Tdap vaccine

BIOLOGICAL7 trials

Conditions

Atopic DermatitisCOVID-19 VaccinesDermatitis AtopicDiphtheriaHuman Papillomavirus InfectionMeningococcal MeningitisPertussisPertussis (Whooping Cough)

Early Phase 1

Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai Women

CompletedNCT03498300

Mahidol UniversityPertussis, Pregnancy Related

Start: 2018-05-09End: 2019-04-13Updated: 2020-03-24

Phase 1

A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)

Not yet recruitingNCT07492303

Changchun BCHT Biotechnology Co.Diphtheria, Pertussis (Whooping Cough), Tetanus

Start: 2026-04-20End: 2027-08-20Target: 96Updated: 2026-03-25

Phase 2

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

CompletedNCT03562377

LEO PharmaAtopic Dermatitis

Start: 2018-07-13End: 2019-11-22Updated: 2025-03-11

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

CompletedNCT06015308

SanofiDermatitis Atopic

Start: 2023-10-06End: 2026-01-16Updated: 2026-08-10

GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age

Not yet recruitingNCT06494475

Minervax ApSStreptococcus Agalactiae Infection

Start: 2024-12-17End: 2025-06-21Target: 564Updated: 2024-07-10

Phase 3

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents

CompletedNCT00518180

Novartis VaccinesHuman Papillomavirus Infection, Meningococcal Meningitis, Pertussis +1

Start: 2007-07-31End: 2008-10-31Updated: 2016-05-18

Phase 4

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age

RecruitingNCT07730450

BioNTech SECOVID-19 Vaccines

Start: 2026-07-23End: 2027-08-20Target: 200Updated: 2026-08-07

British Journal of Dermatology2024-08-013 citations

Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials

SKIN The Journal of Cutaneous Medicine2024-03-183 citations

555 - Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials

British Journal of Dermatology2024-02-011 citations

Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials

British Journal of Dermatology2022-09-0968 citations

Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis.

2021-03-1730 citations